Position in VIR
as of Mar 31, 2026
· filed May 18, 2026
Position Value
$24,592,637
+$23,332,637 QoQ
Shares Held
2,744,714
+997.9% QoQ
Ownership
1.63%
of shares outstanding
% of Portfolio
1.55%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in VIR Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026ADAR1 Capital Management, LLC holds $1,358,769,126 across 212 Biotechnology names. VIR ranks #12 (1.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
1,394,019 | $155,224,015 | |
| 2 | PTGX |
Protagonist Therapeutics, Inc
|
994,119 | $104,780,142 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
3,285,906 | $91,019,596 | |
| 4 | IMVT |
Immunovant, Inc.
|
2,679,010 | $66,546,608 | |
| 5 | TERN |
Terns Pharmaceuticals, Inc.
|
914,699 | $48,222,931 | |
| 6 | CYTK |
Cytokinetics Inc
|
632,556 | $41,691,765 | |
| 7 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
1,139,331 | $41,380,501 | |
| 8 | DNLI |
Denali Therapeutics Inc.
|
1,871,455 | $35,931,936 |
All Filings in VIR
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $24,592,637 | 2,744,714 | Shares | Sole | 2026-05-18 | |
| 2025-06-30 | $1,260,000 | 250,000 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $1,620,000 | 250,000 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $470,251 | 64,067 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $2,390,695 | 319,185 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $979,000 | 110,000 | Shares | Sole | 2024-08-13 | |
| No filing history on record for this holder in this stock. | ||||||